^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    NeoTCR-P1

    i
    Associations
    News

    Trials

    Company:
    PACT Pharma
    Drug class:
    TCR modulator, T lymphocyte replacement
    Related drugs:
    Associations
    News

    Trials

    Apply
    A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors (NCT03970382)
    Phase 1a/1b
    PACT Pharma, Inc.
    Suspended
    Last update posted :
    08/18/2022
    Initiation :
    07/03/2019
    Primary completion :
    08/12/2022
    Completion :
    08/12/2022
    IL2
    |
    Opdivo (nivolumab) • Proleukin (aldesleukin) • NeoTCR-P1